266 related articles for article (PubMed ID: 30640723)
1. A novel alternative splicing-based prediction model for uteri corpus endometrial carcinoma.
Gao L; Xie ZC; Pang JS; Li TT; Chen G
Aging (Albany NY); 2019 Jan; 11(1):263-283. PubMed ID: 30640723
[TBL] [Abstract][Full Text] [Related]
2. A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
Zhou M; Zhang Z; Zhao H; Bao S; Sun J
BMC Cancer; 2018 Jan; 18(1):39. PubMed ID: 29304762
[TBL] [Abstract][Full Text] [Related]
3. Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma.
Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
Cancer Med; 2018 Nov; 7(11):5632-5642. PubMed ID: 30306731
[TBL] [Abstract][Full Text] [Related]
4. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
[TBL] [Abstract][Full Text] [Related]
6. Prognostic index of aberrant mRNA splicing profiling acts as a predictive indicator for hepatocellular carcinoma based on TCGA SpliceSeq data.
Wu HY; Peng ZG; He RQ; Luo B; Ma J; Hu XH; Dang YW; Chen G; Pan SL
Int J Oncol; 2019 Aug; 55(2):425-438. PubMed ID: 31268164
[TBL] [Abstract][Full Text] [Related]
7. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
Zhang D; Duan Y; Wang Z; Lin J
Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
[TBL] [Abstract][Full Text] [Related]
8. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
Sun XX; Wen HQ; Zhan BX; Yang P
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
[TBL] [Abstract][Full Text] [Related]
9. The landscape and prognostic value of immune characteristics in uterine corpus endometrial cancer.
Liu W; Sun L; Zhang J; Song W; Li M; Wang H
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33782686
[TBL] [Abstract][Full Text] [Related]
10. Identification of a prognostic alternative splicing signature in oral squamous cell carcinoma.
Zhang S; Wu X; Diao P; Wang C; Wang D; Li S; Wang Y; Cheng J
J Cell Physiol; 2020 May; 235(5):4804-4813. PubMed ID: 31637730
[TBL] [Abstract][Full Text] [Related]
11. A 14-Methylation-Driven Differentially Expressed RNA as a Signature for Overall Survival Prediction in Patients with Uterine Corpus Endometrial Carcinoma.
Zeng Z; Cheng J; Ye Q; Zhang Y; Shen X; Cai J; Li M
DNA Cell Biol; 2020 Jun; 39(6):975-991. PubMed ID: 32397815
[TBL] [Abstract][Full Text] [Related]
12. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
13. Whole Genome Analysis and Prognostic Model Construction Based on Alternative Splicing Events in Endometrial Cancer.
Wang C; Zheng M; Wang S; Nie X; Guo Q; Gao L; Li X; Qi Y; Liu J; Lin B
Biomed Res Int; 2019; 2019():2686875. PubMed ID: 31355251
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel prognostic alternative splicing signature in papillary renal cell carcinoma.
Duan Y; Zhang D
J Cell Biochem; 2020 Jan; 121(1):672-689. PubMed ID: 31407370
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis of ESRRA in Endometrial Cancer.
Wang S; Huo X
Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981
[TBL] [Abstract][Full Text] [Related]
17. ALDH2 promotes uterine corpus endometrial carcinoma proliferation and construction of clinical survival prognostic model.
Cui YQ; Xiang Y; Meng F; Ji CH; Xiao R; Li JP; Dai ZT; Liao XH
Aging (Albany NY); 2021 Oct; 13(20):23588-23602. PubMed ID: 34670872
[TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
19. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
20. A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma.
Chen Z; Huang X; Lv Y; Fang Y; Pan L; Gan Z; Huang Z; Wei W
Comb Chem High Throughput Screen; 2021; 24(2):187-194. PubMed ID: 32748742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]